Drug-development software company
Appears in 1 story
Target of the buyout; to be taken private
Simulations Plus has traded on the Nasdaq stock market since 2004. On June 16, 2026, it agreed to leave public markets. The healthcare investment firm Altaris will buy the drug-simulation software maker for about $375 million and take it private.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
